Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus

被引:144
作者
Noël, V [1 ]
Lortholary, O [1 ]
Casassus, P [1 ]
Cohen, P [1 ]
Généreau, T [1 ]
André, MH [1 ]
Mouthon, L [1 ]
Guillevin, L [1 ]
机构
[1] Univ Paris 13, Hop Avicenne, Federat Med Interne,Malad Infect & Trop, F-93009 Bobigny, France
关键词
D O I
10.1136/ard.60.12.1141
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives-To describe infectious complications and analyse their risk factors and prognostic role in adults with systemic lupus erythematosus (SLE). Methods-A monocentric cohort of 87 adults with SLE (1960-1997) was studied to determine the risk factors for infection (disease activity evaluated by SLAM and SLEDAI scores, type of organ(s) involved or any biological abnormality, specific treatments) by comparing patients who had suffered at least one infectious episode (n=35; 40%) with non-infected patients (n=52; 60%). Prognostic indicators were assessed by comparing survivors at 10 years with non-survivors. Results-Of the 57 infectious episodes, 47 (82%) were of bacterial origin, 16 (28%) were pneumonia, and 46 (81%) were community acquired. According to univariate analysis, significant risk factors for infection were: severe flares, lupus glomerulonephritis, oral or intravenous corticosteroids, pulse cyclophosphamide, and/or plasmapheresis. No predictors were identified at the time of SLE diagnosis. Multivariate analyses retained intravenous corticosteroids (p <0.001) and/or immunosuppressants (p <0.01) as independent risk factors for infection, which was the only factor for death after 10 years of evolution (p <0.001). Conclusion-In adults with SLE, infections are common and most often caused by community acquired bacteria. Intravenous corticosteroids and immunosuppressants are independent risk factors for infection, which is the only independent risk factor for death after 10 years of SLE evolution.
引用
收藏
页码:1141 / 1144
页数:4
相关论文
共 15 条
  • [1] Morbidity and mortality in systemic lupus erythematosus during a 5-year period -: A multicenter prospective study of 1,000 patients
    Cervera, R
    Khamashta, MA
    Font, J
    Sebastiani, GD
    Gil, A
    Lavilla, P
    Aydintug, AO
    Jedryka-Góral, A
    de Ramón, E
    Fernández-Nebro, A
    Galeazzi, M
    Haga, HJ
    Mathieu, A
    Houssiau, F
    Ruiz-Irastorza, G
    Ingelmo, M
    Hughes, GRV
    [J]. MEDICINE, 1999, 78 (03) : 167 - 175
  • [2] Methodological issues of corticosteroid use in SLE clinical trials
    Corzillius, M
    Bae, SC
    [J]. LUPUS, 1999, 8 (08) : 692 - 697
  • [3] COMPUTER-ANALYSIS OF FACTORS INFLUENCING FREQUENCY OF INFECTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    GINZLER, E
    DIAMOND, H
    KAPLAN, D
    WEINER, M
    SCHLESINGER, M
    SELEZNICK, M
    [J]. ARTHRITIS AND RHEUMATISM, 1978, 21 (01): : 37 - 44
  • [4] GODEAU B, 1994, J RHEUMATOL, V21, P246
  • [5] FATAL INFECTIONS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - THE ROLE OF OPPORTUNISTIC ORGANISMS
    HELLMANN, DB
    PETRI, M
    WHITINGOKEEFE, Q
    [J]. MEDICINE, 1987, 66 (05) : 341 - 348
  • [6] Hernández-Cruz B, 1999, CLIN EXP RHEUMATOL, V17, P289
  • [7] Immunopathogenesis and spectrum of infections in systemic lupus erythematosus
    Iliopoulos, AG
    Tsokos, GC
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 1996, 25 (05) : 318 - 336
  • [8] MANDELL G, 2000, PRINCIPLES PRACTICE
  • [9] NIVED O, 1985, Q J MED, V55, P271
  • [10] Update on cyclophosphamide for systemic lupus erythematosus
    Ortmann, RA
    Klippel, JH
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) : 363 - +